[{"from": "human", "value": "Could you give me a brief overview of this molecule? [C][C@H1][C][N][Branch2][=Branch1][=Branch2][C][C][N][Ring1][=Branch1][C][=C][N][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][N][C][=C][C][=Branch1][#Branch2][=C][N][Branch1][Branch1][C][Ring1][=Branch1][=O][C][C][=C][Branch2][Ring2][Ring2][C][=Branch1][=Branch1][=N][C][=C][Ring1][=Branch1][N][C][C][N][C][=C][Branch1][N][C][C][Branch1][Ring2][C][Ring1][Branch1][Branch1][C][C][C][C][=C][Ring1][#Branch2][C][Ring1][=C][=O][C][O][C][C][O][C][Ring1][Ring2]"}, {"from": "gpt", "value": "The molecule is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, fenebrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival."}]